GlassScriptPhysician profile
John Edward Hartmann
NPI 1982694998
$537.42
in general payments reported to CMS, 2019-2025
14 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.71 · 2020: $12.06 · 2021: $33.39 · 2022: $72.76 · 2023: $81.91 · 2024: $126 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $124.55 | 2025 | Rystiggo |
| Abbvie INC. | $82.31 | 2023-2025 | |
| Boston Scientific Corporation | $59.62 | 2023 | |
| Sk Life Science, INC. | $55.16 | 2024 | |
| Amgen INC. | $54.01 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $41.12 | 2022-2024 | Ultomiris |
| Biogen, INC. | $22.34 | 2021 | |
| Neurocrine Biosciences, INC. | $17.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.93 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.27 | 2025 | |
| Octapharma USA, INC. | $13.75 | 2024 | Panzyga |
| Tanabe Pharma America, INC. | $12.74 | 2019 | |
| Acorda Therapeutics, INC | $12.06 | 2020 | |
| Natus Medical Incorporated | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hartmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.